Add like
Add dislike
Add to saved papers

Prognostic Significance of Number of Lymph Node Metastasis on Survival in Patients with Pathological T3 Esophageal Carcinoma.

Neoplasma 2016 November 25
The aim of this study was to evaluate the impact of the number of metastatic lymph nodes (MLN) and other risk factors on survival in patients with pathological T3 (pT3) esophageal carcinoma who were treated by esophagectomy. We analyzed 70 patients who received primary curative resection for pT3 esophageal cancer from 1997 to 2011. The prognostic role of age, gender, tumor location, cell type, pathological lymph node status (pN), number of MLNs (<3 vs ≥3), metastatic lymph node ratio (MLR), type of resection, local recurrence, and distant metastasis on overall survival (OS) were examined by univariate and multivariate analyses. Survival curves were calculated using Kaplan-Meier method and survival differences were assessed by log-rank test. A receiver operating characteristic analysis was used to determine the optimum cut-off point for the MLR. The median follow-up time was 41 (range, 8-128) months, and the 1-, 3- and 5-year OS rates were 78.6%, 38.1%, and 22.5%, respectively. Tumor location, pN, the number of MLNs, local recurrence, and distant metastasis had a significant effect on OS in the univariate analysis. In the multivariate model, the number of MLNs (p=0.02; hazard ratio (HR), 2.1; 95% confidence interval (CI), 1.1-4.1) and distant metastasis (p=0.007; HR, 5.1; 95% CI, 1.5-16.8) were independent risk factors for OS. Patients with pT3 esophageal cancer who have 3 or more MLNs and distant metastasis have a poor OS, and this result can be used as a factor for better estimation of prognosis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

Managing Alcohol Withdrawal Syndrome.Annals of Emergency Medicine 2024 March 26

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app